Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Soliris
Pharma
Why is AstraZeneca's variant-busting COVID med underachieving?
AstraZenca reported second quarter sales of Evusheld came in at $445 million—a decline from the $469 million it generated in the first quarter.
Kevin Dunleavy
Jul 29, 2022 11:09am
Argenx's Vyvgart launch faces 'fierce' Ultomiris battle: analyst
Jul 27, 2022 8:40am
AZ's rare disease rising star Ultomiris snags 3rd FDA nod
Apr 28, 2022 9:15am
AZ, on a roll with Ultomiris, shares new data in gMG
Apr 6, 2022 11:06am
Horizon taps 'MasterChef' winner to spotlight eye disease
Mar 7, 2022 11:53am
Argenx straddles the line between drug promotion and awareness
Mar 3, 2022 10:10am
